GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nexien BioPharma Inc (OTCPK:NXEN) » Definitions » Cash Flow from Investing

Nexien BioPharma (Nexien BioPharma) Cash Flow from Investing : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Nexien BioPharma Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Nexien BioPharma spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Nexien BioPharma gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Nexien BioPharma Cash Flow from Investing Historical Data

The historical data trend for Nexien BioPharma's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexien BioPharma Cash Flow from Investing Chart

Nexien BioPharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Flow from Investing
Get a 7-Day Free Trial -0.03 - - - -

Nexien BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nexien BioPharma Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Nexien BioPharma's Cash Flow from Investing for the fiscal year that ended in Jun. 2023 is calculated as:

Nexien BioPharma's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nexien BioPharma  (OTCPK:NXEN) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Nexien BioPharma's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Nexien BioPharma spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Nexien BioPharma's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Nexien BioPharma gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Nexien BioPharma's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Nexien BioPharma spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Nexien BioPharma's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Nexien BioPharma gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Nexien BioPharma's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Nexien BioPharma spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Nexien BioPharma's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Nexien BioPharma gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Nexien BioPharma's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Nexien BioPharma paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Nexien BioPharma's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Nexien BioPharma paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Nexien BioPharma's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Nexien BioPharma paid $0.00 Mil for other investing activities.


Nexien BioPharma Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Nexien BioPharma's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Nexien BioPharma (Nexien BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
4340 East Kentucky Avenue, Suite 206, Glendale, CO, USA, 80246
Nexien BioPharma Inc is a researcher and developer of cannabinoid-based pharmaceutical for various medical conditions and disorders, all under U.S. Food and Drug Administration development pathways.
Executives
Jeffrey Friedland other: Former 10% Owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Usa Inc. 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Inc. 10 percent owner 4340 E. KENTUCKY AVE., SUITE 206, GLENDALE CO 80246
Joseph F Aceto officer: VP Legal & IP Counsel 1617 NEWARK ROAD, KENNETT SQUARE PA 19348
Jeremy Robert Reeh officer: VP Translational Research 11 TANKARD LANE, WASHINGTON CROSSING PA 18977
Alexander Michael Wasyl director, officer: Chief Executive Officer 31 BEIDLER DRIVE, WASHINGTON CROSSING PA 18977
Frank J Manganella officer: VP Corporate Development 148-26 10TH AVENUE, WHITESTONE NY 11357
Clark Courtney Lynne director PO BOX 7801, ASPEN CO 81612
Lindy Snider director 408 BARBARA LANE, BRYN MAWR PA 19010
Robert I Goldfarb officer: Chief Operating Officer 230 GOLDEN BEACH DRIVE, GOLDEN BEACH FL 33160
Evan L Wasoff officer: Chief Financial Officer 101 WINGER DRIVE, NEDERLAND CO 80466
Alain D Bankier director 150 COLUMBUS AVENUE APT 17F, NEW YORK NY 10023
Richard S Greenberg director, 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Ivo Heiden director, 10 percent owner 2275 HUNTINGTON DRIVE, SUITE 851, SAN MARINO CA 91108